Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

LabNews Media LLC

The Editors in Chief of lab-news.de are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

LabNews Media LLC

Stay Connected

Unmatched reporting

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

LabNews Media LLC

Ähnliche Beiträge

Wissenschaftliche Evidenz zum Hautkrebs-Screening in Deutschland

Editorial: Backhaus’ fortgesetzte Verletzung der Garantenpflicht

Blockchain erobert die Biomedizin

Stay Connected

Unmatched reporting